Specialty code 183500000X · Santa Rosa, CA
NPI
1538341466
Since 2007
Specialty
Specialty code 183500000X
Code 183500000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
401 Bicentennial Way Ste 315, Anticoagulation Clinic
Santa Rosa, CA, 95403
Phone (707) 571-3287
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$364K
1,626 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Linda H Quang prescribed most often to Medicare patients was Atorvastatin Calcium, with 174 prescriptions and refills. In total Linda H Quang wrote 1,626 Medicare prescriptions that cost $364K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-12-03.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Atorvastatin Calcium Generic | 174 | 575 | 92 | $2,191 |
| Ozempic Semaglutide | 137 | 140 | 30 | $101K |
| Metformin Hcl Er Metformin Hcl | 130 | 421 | 74 | $1,318 |
| Jardiance Empagliflozin | 115 | 353 | 50 | $64K |
| Metformin Hcl Generic | 109 | 359 | 50 | $1,466 |
| Humulin N Insulin Nph Human Isophane | 94 | 273 | 57 | $14K |
| Glipizide Generic | 89 | 282 | 47 | $1,055 |
| Victoza 2-Pak Liraglutide | 74 | 77 | 23 | $46K |
| Liraglutide Generic | 63 | 65 | 23 | $44K |
| Insulin Glargine-Yfgn Generic | 59 | 165 | 31 | $7,898 |
| Ultra-Fine Nano Pen Needle Pen Needle, Diabetic | 58 | 164 | 32 | $1,636 |
| Glipizide Er Glipizide | 53 | 176 | 26 | $1,816 |
| Lisinopril Generic | 47 | 157 | 19 | $562 |
| Veo Insulin Syringe Syringe-Needle,insulin,0.5 Ml | 46 | 149 | 26 | $1,293 |
| Humalog Kwikpen U-100 Insulin Lispro | 46 | 112 | 17 | $20K |
Brand drugs: 714 claims; generic drugs: 758 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Linda H Quang were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.